{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:36:13Z","timestamp":1784939773078,"version":"3.55.0"},"reference-count":100,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Leishmaniasis is one of the Neglected Tropical Diseases (NTDs), a zoonotic disease of\nvector-borne nature that is caused by a protozoan parasite Leishmania. This parasite is transmitted\nby the vector sandfly into the human via a bite. Visceral leishmaniasis (VL), also called kala-azar,\nis the most fatal among the types of leishmaniasis, with high mortality mostly spread in the East\nAfrica and South Asia regions. WHO report stated that approximately 3.3 million disabilities occur\nevery year due to the disease along with approximately 50,000 annual deaths. The real matter\nof concern is that there is no particular effective medicine\/vaccine available against leishmaniasis\nto date except a few approved drugs and chemotherapy for the infected patient. The current selection\nof small compounds was constrained, and their growing drug resistance had been a major worry.\nAdditionally, the serious side effects on humans of the available therapy or drugs have made it\nessential to discover efficient and low-cost methods to speed up the development of new drugs\nagainst leishmaniasis. Ideally, the vaccine could be a low risk and effective alternative for both\nCL and VL and elicit long-lasting immunity against the disease. There are a number of vaccine\ncandidates at various stages of clinical development and preclinical stage. However, none has successfully\npassed all clinical trials. But, the successful development and approval of commercially\navailable vaccines for dogs against canine leishmaniasis (CanL) provides evidence that it can be\npossible for humans in distant future. In the present article, the approaches used for the development\nof vaccines for leishmaniasis are discussed and the progress being made is briefly reviewed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113894501254585230927100440","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T11:55:08Z","timestamp":1697111708000},"page":"1023-1031","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Review on the Drug Intolerance and Vaccine Development for the\nLeishmaniasis"],"prefix":"10.2174","volume":"24","author":[{"given":"Priya","family":"Kumari","sequence":"first","affiliation":[{"name":"Centre of Sustainable Polymers, Indian Institute of Technology, Guwahati, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrin","family":"Mamud","sequence":"additional","affiliation":[{"name":"Department of Molecular\nBiology and Biotechnology, Tezpur University, Tezpur, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2304-2468","authenticated-orcid":true,"given":"Anupam Nath","family":"Jha","sequence":"additional","affiliation":[{"name":"Department of Molecular\nBiology and Biotechnology, Tezpur University, Tezpur, Assam, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21767\/1791-809X.1000519","volume":"11","author":"Alemayehu B.","year":"2017","unstructured":"Alemayehu B.; Alemayehu M.; Leishmaniasis: A review on parasite, vector and reservoir host. Health Sci J 2017,11(4),1","journal-title":"Health Sci J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.12688\/f1000research.11120.1","volume":"6","author":"Torres-Guerrero E.","year":"2017","unstructured":"Torres-Guerrero E.; Quintanilla-Cedillo M.R.; Ruiz-Esmenjaud J.; Arenas R.; Leishmaniasis: A review. F1000 Res 2017,6,750","journal-title":"F1000 Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41540-018-0059-y","volume":"4","author":"Mazein A.","year":"2018","unstructured":"Mazein A.; Ostaszewski M.; Kuperstein I.; Watterson S.; Le Nov&#xE8;re N.; Lefaudeux D.; De Meulder B.; Pellet J.; Balaur I.; Saqi M.; Nogueira M.M.; He F.; Parton A.; Lemonnier N.; Gawron P.; Gebel S.; Hainaut P.; Ollert M.; Dogrusoz U.; Barillot E.; Zinovyev A.; Schneider R.; Balling R.; Auffray C.; Systems medicine disease maps: Community-driven comprehensive representation of disease mechanisms. NPJ Syst Biol Appl 2018,4(1),21","journal-title":"NPJ Syst Biol Appl"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3855\/jidc.4310","volume":"8","author":"Elmahallawy E.K.","year":"2014","unstructured":"Elmahallawy E.K.; Sampedro Martinez A.; Rodriguez-Granger J.; Hoyos-Mallecot Y.; Agil A.; Navarro Mari J.M.; Gutierrez Fernandez J.; Diagnosis of leishmaniasis. J Infect Dev Ctries 2014,8(8),961-972","journal-title":"J Infect Dev Ctries"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2174\/1389450121666200422083735","volume":"21","author":"Mansuri R.","year":"2020","unstructured":"Mansuri R.; Singh J.; Diwan A.; An insight into the current perspective and potential drug targets for visceral leishmaniasis (VL). Curr Drug Targets 2020,21(11),1105-1129","journal-title":"Curr Drug Targets"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/1871526516666161230124513","volume":"17","author":"Kashif M.","year":"2017","unstructured":"Kashif M.; Screening of novel inhibitors against Leishmania donovani calcium ion channel to fight leishmaniasis. Infect Disord Drug Targets 2017,17(2),120-129","journal-title":"Infect Disord Drug Targets"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"6456031","DOI":"10.1155\/2016\/6456031","volume":"2016","author":"Hoyos C.L.","year":"2016","unstructured":"Hoyos C.L.; Epidemiology of American tegumentary leishmaniasis and Trypanosoma cruzi infection in the Northwestern Argentina. Biomed Res Int 2016,2016,6456031","journal-title":"Biomed Res Int"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","volume":"27","author":"Desjeux P.","year":"2004","unstructured":"Desjeux P.; Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004,27(5),305-318","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0035-9203(01)90223-8","volume":"95","author":"Desjeux P.","year":"2001","unstructured":"Desjeux P.; The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001,95(3),239-243","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/iub.1759","volume":"70","author":"Saha A.","year":"2018","unstructured":"Saha A.; Basu M.; Ukil A.; Recent advances in understanding Leishmania donovani infection: The importance of diverse host regulatory pathways. IUBMB Life 2018,70(7),593-601","journal-title":"IUBMB Life"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jip.2005.05.007","volume":"89","author":"Poinar G.","year":"2005","unstructured":"Poinar G.; Poinar R.; Fossil evidence of insect pathogens. J Invertebr Pathol 2005,89(3),243-250","journal-title":"J Invertebr Pathol"},{"key":"ref=12","author":"Cox F.","year":"1994","unstructured":"Cox F.; Lee D.;  Modern Parasitology: A Textbook of Parasitology 1994","journal-title":"Modern Parasitology: A Textbook of Parasitology"},{"key":"ref=13","first-page":"345","volume":"53","author":"Channon J.Y.","year":"1984","unstructured":"Channon J.Y.; Roberts M.B.; Blackwell J.M.; A study of the differential respiratory burst activity elicited by promastigotes and amastigotes of Leishmania donovani in murine resident peritoneal macrophages. Immunology 1984,53(2),345-355","journal-title":"Immunology"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.pt.2007.06.009","volume":"23","author":"McConville M.J.","year":"2007","unstructured":"McConville M.J.; de Souza D.; Saunders E.; Likic V.A.; Naderer T.; Living in a phagolysosome; metabolism of Leishmania amastigotes. Trends Parasitol 2007,23(8),368-375","journal-title":"Trends Parasitol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nature01152","volume":"420","author":"Belkaid Y.","year":"2002","unstructured":"Belkaid Y.; Piccirillo C.A.; Mendez S.; Shevach E.M.; Sacks D.L.; CD4CD25 regulatory T cells control Leishmania major persistence and immunity. Nature 2002,420(6915),502-507","journal-title":"Nature"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1172\/JCI79526","volume":"125","author":"Gurung P.","year":"2015","unstructured":"Gurung P.; Karki R.; Vogel P.; Watanabe M.; Bix M.; Lamkanfi M.; Kanneganti T.D.; An NLRP3 inflammasome\u2013triggered Th2-biased adaptive immune response promotes leishmaniasis. J Clin Invest 2015,125(3),1329-1338","journal-title":"J Clin Invest"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.0105-2896.2004.00185.x","volume":"201","author":"Sacks D.","year":"2004","unstructured":"Sacks D.; Anderson C.; Re-examination of the immunosuppressive mechanisms mediating non-cure of Leishmania infection in mice. Immunol Rev 2004,201(1),225-238","journal-title":"Immunol Rev"},{"key":"ref=18","first-page":"213","volume":"1","author":"Chang K.-P.","year":"1985","unstructured":"Chang K.-P.; Hendricks L.; Laboratory cultivation and maintenance of Leishmania. Human Parasitic Dis 1985,1,213-244","journal-title":"Human Parasitic Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0020-7519(03)00142-5","volume":"33","author":"Gossage S.M.","year":"2003","unstructured":"Gossage S.M.; Rogers M.E.; Bates P.A.; Two separate growth phases during the development of Leishmania in sand flies: Implications for understanding the life cycle. Int J Parasitol 2003,33(10),1027-1034","journal-title":"Int J Parasitol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"e0004349","DOI":"10.1371\/journal.pntd.0004349","volume":"10","author":"Akhoundi M.","year":"2016","unstructured":"Akhoundi M.; Kuhls K.; Cannet A.; Vot&#xFD;pka J.; Marty P.; Delaunay P.; Sereno D.; A historical overview of the classification, evolution, and dispersion of Leishmania parasites and sandflies. PLoS Negl Trop Dis 2016,10(3),e0004349","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2174\/1381612023396230","volume":"8","author":"Vannier-Santos M.","year":"2002","unstructured":"Vannier-Santos M.; Martiny A.; Souza W.; Cell biology of Leishmania spp.: Invading and evading. Curr Pharm Des 2002,8(4),297-318","journal-title":"Curr Pharm Des"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.mib.2010.05.008","volume":"13","author":"Gluenz E.","year":"2010","unstructured":"Gluenz E.; Ginger M.L.; McKean P.G.; Flagellum assembly and function during the Leishmania life cycle. Curr Opin Microbiol 2010,13(4),473-479","journal-title":"Curr Opin Microbiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.ijpara.2007.04.003","volume":"37","author":"Bates P.A.","year":"2007","unstructured":"Bates P.A.; Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int J Parasitol 2007,37(10),1097-1106","journal-title":"Int J Parasitol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1183034","DOI":"10.3389\/fgene.2023.1183034","volume":"14","author":"Jha A.N.","year":"2023","unstructured":"Jha A.N.; Editorial: Computational approaches to build therapeutic paradigms targeting genes, proteins and pathways against neglected tropical diseases (NTDs). Front Genet 2023,14,1183034","journal-title":"Front Genet"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"104851","DOI":"10.1016\/j.compbiomed.2021.104851","volume":"137","author":"Shaker B.","year":"2021","unstructured":"Shaker B.; Ahmad S.; Lee J.; Jung C.; Na D.; in silico methods and tools for drug discovery. Comput Biol Med 2021,137,104851","journal-title":"Comput Biol Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1093\/bib\/bbz103","volume":"21","author":"Agamah F.E.","year":"2020","unstructured":"Agamah F.E.; Mazandu G.K.; Hassan R.; Bope C.D.; Thomford N.E.; Ghansah A.; Chimusa E.R.; Computational\/in silico methods in drug target and lead prediction. Brief Bioinform 2020,21(5),1663-1675","journal-title":"Brief Bioinform"},{"key":"ref=27","author":"Hazarika Z.","year":"2020","unstructured":"Hazarika Z.; Rajkhowa S.; Jha A.N.;  Homology Molecular Modeling-Perspectives and Applications 2020","journal-title":"Homology Molecular Modeling-Perspectives and Applications"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1109\/ComPE49325.2020.9200180","author":"Hazarika Z.","year":"2020","unstructured":"Hazarika Z.; Jha A.N.; A Comparative Evaluation of Docking Programs using Influenza Endonuclease as Target Protein. 2020 International Conference on Computational Performance Evaluation (ComPE) 2020","journal-title":"2020 International Conference on Computational Performance Evaluation (ComPE)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"114425","DOI":"10.1016\/j.jphotochem.2022.114425","volume":"436","author":"Lyndem S.","year":"2023","unstructured":"Lyndem S.; Hazarika U.; Athul P.; Bhatta A.; Prakash V.; Jha A.N.; Singha Roy A.; A comprehensive in vitro exploration into the interaction mechanism of coumarin derivatives with bovine hemoglobin: Spectroscopic and computational methods. J Photochem Photobiol Chem 2023,436,114425","journal-title":"J Photochem Photobiol Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"100146","DOI":"10.1016\/j.medidd.2022.100146","volume":"16","author":"Indari O.","year":"2022","unstructured":"Indari O.; Kumar Singh A.; Tiwari D.; Chandra Jha H.; Nath Jha A.; Deciphering antiviral efficacy of malaria box compounds against malaria exacerbating viral pathogens- Epstein Barr virus and SARS-CoV-2, an in silico study. Medicine in Drug Discovery 2022,16,100146","journal-title":"Medicine in Drug Discovery"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"106908","DOI":"10.1016\/j.bpc.2022.106908","volume":"291","author":"Borkotoky S.","year":"2022","unstructured":"Borkotoky S.; Dey D.; Hazarika Z.; Joshi A.; Tripathi K.; Unravelling viral dynamics through molecular dynamics simulations - A brief overview. Biophys Chem 2022,291,106908","journal-title":"Biophys Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"548","DOI":"10.2174\/1389203723666220822152141","volume":"23","author":"Jha A.N.","year":"2022","unstructured":"Jha A.N.; Hazarika Z.; Saikia S.; Interaction of Nanomaterials with Protein-Peptide. Curr Protein Pept Sci 2022,23(8),548-562","journal-title":"Curr Protein Pept Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/1389203724666230210123147","volume":"24","author":"Kumari I.","year":"2023","unstructured":"Kumari I.; Lakhanpal D.; Swargam S.; Nath Jha A.; Leishmaniasis: Omics Approaches to Understand its Biology from Molecule to Cell Level. Curr Protein Pept Sci 2023,24(3),229-239","journal-title":"Curr Protein Pept Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/ng2053","volume":"39","author":"Peacock C.S.","year":"2007","unstructured":"Peacock C.S.; Seeger K.; Harris D.; Murphy L.; Ruiz J.C.; Quail M.A.; Peters N.; Adlem E.; Tivey A.; Aslett M.; Kerhornou A.; Ivens A.; Fraser A.; Rajandream M.A.; Carver T.; Norbertczak H.; Chillingworth T.; Hance Z.; Jagels K.; Moule S.; Ormond D.; Rutter S.; Squares R.; Whitehead S.; Rabbinowitsch E.; Arrowsmith C.; White B.; Thurston S.; Bringaud F.; Baldauf S.L.; Faulconbridge A.; Jeffares D.; Depledge D.P.; Oyola S.O.; Hilley J.D.; Brito L.O.; Tosi L.R.O.; Barrell B.; Cruz A.K.; Mottram J.C.; Smith D.F.; Berriman M.; Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat Genet 2007,39(7),839-847","journal-title":"Nat Genet"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.parint.2006.09.001","volume":"56","author":"Sereno D.","year":"2007","unstructured":"Sereno D.; Cordeiro da Silva A.; Mathieu-Daude F.; Ouaissi A.; Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol Int 2007,56(1),3-7","journal-title":"Parasitol Int"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"7761","DOI":"10.3390\/molecules18077761","volume":"18","author":"Ogungbe I.","year":"2013","unstructured":"Ogungbe I.; Setzer W.; in-silico Leishmania target selectivity of antiparasitic terpenoids. Molecules 2013,18(7),7761-7847","journal-title":"Molecules"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2174\/138955751503150312141854","volume":"15","author":"Scotti L.","year":"2015","unstructured":"Scotti L.; Ishiki H.; Mendonca F.J.B.; Silva M.S.; Scotti M.T.; In-silico analyses of natural products on leishmania enzyme targets. Mini Rev Med Chem 2015,15(3),253-269","journal-title":"Mini Rev Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"607139","DOI":"10.3389\/fchem.2021.607139","volume":"9","author":"dos Santos Vasconcelos C.R.","year":"2021","unstructured":"dos Santos Vasconcelos C.R.; Rezende A.M.; Systematic in silico evaluation of Leishmania spp. proteomes for drug discovery. Front Chem 2021,9,607139","journal-title":"Front Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12639-010-0006-3","volume":"34","author":"Chawla B.","year":"2010","unstructured":"Chawla B.; Madhubala R.; Drug targets in Leishmania. J Parasit Dis 2010,34(1),1-13","journal-title":"J Parasit Dis"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.1002\/pca.3213","volume":"2023","author":"Saha D.","year":"2023","unstructured":"Saha D.; Nath Jha A.; Computational multi-target approach to target essential enzymes of Leishmania donovani using comparative molecular dynamic simulations and MMPBSA analysis. Phytochem Anal 2023,2023(Online ahead of print)","journal-title":"Phytochem Anal"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/jac\/11.2.151","volume":"11","author":"Coombs G.H.","year":"1983","unstructured":"Coombs G.H.; Hart D.T.; Capaldo J.; Leishmania mexicann : Drug sensititvitles of promastigotes and transforming amastigotes. J Antimicrob Chemother 1983,11(2),151-162","journal-title":"J Antimicrob Chemother"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1473-3099(02)00347-X","volume":"2","author":"Guerin P.J.","year":"2002","unstructured":"Guerin P.J.; Olliaro P.; Sundar S.; Boelaert M.; Croft S.L.; Desjeux P.; Wasunna M.K.; Bryceson A.D.M.; Visceral leishmaniasis: Current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002,2(8),494-501","journal-title":"Lancet Infect Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1086\/318121","volume":"31","author":"Sundar S.","year":"2000","unstructured":"Sundar S.; More D.K.; Singh M.K.; Singh V.P.; Sharma S.; Makharia A.; Kumar P.C.K.; Murray H.W.; Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic. Clin Infect Dis 2000,31(4),1104-1107","journal-title":"Clin Infect Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1368-7646(98)80213-6","volume":"1","author":"Ouellette M.","year":"1998","unstructured":"Ouellette M.; L&#xE9;gar&#xE9; D.; Haimeur A.; Grondin K.; Roy G.; Brochu C.; Papadopoulou B.; ABC transporters in Leishmania and their role in drug resistance. Drug Resist Updat 1998,1(1),43-48","journal-title":"Drug Resist Updat"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1128\/AAC.42.12.3097","volume":"42","author":"Sereno D.","year":"1998","unstructured":"Sereno D.; Cavaleyra M.; Zemzoumi K.; Maquaire S.; Ouaissi A.; Lemesre J.L.; Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother 1998,42(12),3097-3102","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"31010","DOI":"10.1074\/jbc.M403959200","volume":"279","author":"Gourbal B.","year":"2004","unstructured":"Gourbal B.; Sonuc N.; Bhattacharjee H.; Legare D.; Sundar S.; Ouellette M.; Rosen B.P.; Mukhopadhyay R.; Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 2004,279(30),31010-31017","journal-title":"J Biol Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.molbiopara.2008.12.007","volume":"164","author":"Jhingran A.","year":"2009","unstructured":"Jhingran A.; Chawla B.; Saxena S.; Barrett M.P.; Madhubala R.; Paromomycin: Uptake and resistance in Leishmania donovani. Mol Biochem Parasitol 2009,164(2),111-117","journal-title":"Mol Biochem Parasitol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.pt.2003.09.008","volume":"19","author":"Croft S.L.","year":"2003","unstructured":"Croft S.L.; Coombs G.H.; Leishmaniasis\u2013 current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003,19(11),502-508","journal-title":"Trends Parasitol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","volume":"19","author":"Croft S.L.","year":"2006","unstructured":"Croft S.L.; Sundar S.; Fairlamb A.H.; Drug resistance in leishmaniasis. Clin Microbiol Rev 2006,19(1),111-126","journal-title":"Clin Microbiol Rev"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/cid\/cis474","volume":"55","author":"Sundar S.","year":"2012","unstructured":"Sundar S.; Singh A.; Rai M.; Prajapati V.K.; Singh A.K.; Ostyn B.; Boelaert M.; Dujardin J.C.; Chakravarty J.; Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012,55(4),543-550","journal-title":"Clin Infect Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"e1974","DOI":"10.1371\/journal.pntd.0001974","volume":"6","author":"Garc&#xED;a-Hern&#xE1;ndez R.","year":"2012","unstructured":"Garc&#xED;a-Hern&#xE1;ndez R.; Manzano J.I.; Castanys S.; Gamarro F.; Leishmania donovani develops resistance to drug combinations. PLoS Negl Trop Dis 2012,6(12),e1974","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.pt.2016.11.003","volume":"33","author":"Hefnawy A.","year":"2017","unstructured":"Hefnawy A.; Berg M.; Dujardin J.C.; De Muylder G.; Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs. Trends Parasitol 2017,33(3),162-174","journal-title":"Trends Parasitol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ijantimicag.2007.01.004","volume":"29","author":"Natera S.","year":"2007","unstructured":"Natera S.; Machuca C.; Padr&#xF3;n-Nieves M.; Romero A.; D&#xED;az E.; Ponte-Sucre A.; Leishmania spp.: Proficiency of drug-resistant parasites. Int J Antimicrob Agents 2007,29(6),637-642","journal-title":"Int J Antimicrob Agents"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1128\/AAC.45.4.1168-1173.2001","volume":"45","author":"Sereno D.","year":"2001","unstructured":"Sereno D.; Roy G.; Lemesre J.L.; Papadopoulou B.; Ouellette M.; DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 2001,45(4),1168-1173","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"cbdd.13502","DOI":"10.1111\/cbdd.13502","volume":"93","author":"Bora N.","year":"2019","unstructured":"Bora N.; Nath Jha A.; An integrative approach using systems biology, mutational analysis with molecular dynamics simulation to challenge the functionality of a target protein. Chem Biol Drug Des 2019,93(6),cbdd.13502","journal-title":"Chem Biol Drug Des"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fgene.2020.00179","volume":"11","author":"Bora N.","year":"2020","unstructured":"Bora N.; Jha A.N.; In silico metabolic pathway analysis identifying target against leishmaniasis \u2013 A kinetic modeling approach. Front Genet 2020,11,179","journal-title":"Front Genet"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/S0035-9203(02)90063-5","volume":"96","author":"Croft S.L.","year":"2002","unstructured":"Croft S.L.; Yardley V.; Kendrick H.; Drug sensitivity of Leishmania species: Some unresolved problems. Trans R Soc Trop Med Hyg 2002,96(Suppl. 1),S127-S129","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.resmic.2004.01.001","volume":"155","author":"Fumarola L.","year":"2004","unstructured":"Fumarola L.; Spinelli R.; Brandonisio O.; In vitro assays for evaluation of drug activity against Leishmania spp. Res Microbiol 2004,155(4),224-230","journal-title":"Res Microbiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/B978-0-12-821100-7.00018-2","author":"Rajkhowa S.","year":"2021","unstructured":"Rajkhowa S.; Hazarika Z.; Jha A.N.;  Applications of Nanobiotechnology for Neglected Tropical Diseases 2021,509-548","journal-title":"Applications of Nanobiotechnology for Neglected Tropical Diseases"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e1001161","DOI":"10.1371\/journal.ppat.1001161","volume":"6","author":"Lye L.F.","year":"2010","unstructured":"Lye L.F.; Owens K.; Shi H.; Murta S.M.F.; Vieira A.C.; Turco S.J.; Tschudi C.; Ullu E.; Beverley S.M.; Retention and loss of RNA interference pathways in trypanosomatid protozoans. PLoS Pathog 2010,6(10),e1001161","journal-title":"PLoS Pathog"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0031182000078458","volume":"108","author":"Bates P.A.","year":"1994","unstructured":"Bates P.A.; Complete developmental cycle of Leishmania mexicana in axenic culture. Parasitology 1994,108(1),1-9","journal-title":"Parasitology"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.molbiopara.2017.06.005","volume":"216","author":"Duncan S.M.","year":"2017","unstructured":"Duncan S.M.; Jones N.G.; Mottram J.C.; Recent advances in Leishmania reverse genetics: Manipulating a manipulative parasite. Mol Biochem Parasitol 2017,216,30-38","journal-title":"Mol Biochem Parasitol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/mmi.13375","volume":"100","author":"Duncan S.M.","year":"2016","unstructured":"Duncan S.M.; Myburgh E.; Philipon C.; Brown E.; Meissner M.; Brewer J.; Mottram J.C.; Conditional gene deletion with DiCre demonstrates an essential role for CRK3 in L eishmania mexicana cell cycle regulation. Mol Microbiol 2016,100(6),931-944","journal-title":"Mol Microbiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/j.1365-2958.2009.06610.x","volume":"71","author":"Murta S.M.F.","year":"2009","unstructured":"Murta S.M.F.; Vickers T.J.; Scott D.A.; Beverley S.M.; Methylene tetrahydrofolate dehydrogenase\/cyclohydrolase and the synthesis of 10-CHO-THF are essential in Leishmania major. Mol Microbiol 2009,71(6),1386-1401","journal-title":"Mol Microbiol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/348171a0","volume":"348","author":"Cruz A.","year":"1990","unstructured":"Cruz A.; Beverley S.M.; Gene replacement in parasitic protozoa. Nature 1990,348(6297),171-173","journal-title":"Nature"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.1112680","volume":"309","author":"Ivens A.C.","year":"2005","unstructured":"Ivens A.C.; Peacock C.S.; Worthey E.A.; Murphy L.; Aggarwal G.; Berriman M.; Sisk E.; Rajandream M.A.; Adlem E.; Aert R.; Anupama A.; Apostolou Z.; Attipoe P.; Bason N.; Bauser C.; Beck A.; Beverley S.M.; Bianchettin G.; Borzym K.; Bothe G.; Bruschi C.V.; Collins M.; Cadag E.; Ciarloni L.; Clayton C.; Coulson R.M.; Cronin A.; Cruz A.K.; Davies R.M.; De Gaudenzi J.; Dobson D.E.; Duesterhoeft A.; Fazelina G.; Fosker N.; Frasch A.C.; Fraser A.; Fuchs M.; Gabel C.; Goble A.; Goffeau A.; Harris D.; Hertz-Fowler C.; Hilbert H.; Horn D.; Huang Y.; Klages S.; Knights A.; Kube M.; Larke N.; Litvin L.; Lord A.; Louie T.; Marra M.; Masuy D.; Matthews K.; Michaeli S.; Mottram J.C.; M&#xFC;ller-Auer S.; Munden H.; Nelson S.; Norbertczak H.; Oliver K.; O\u2019neil S.; Pentony M.; Pohl T.M.; Price C.; Purnelle B.; Quail M.A.; Rabbinowitsch E.; Reinhardt R.; Rieger M.; Rinta J.; Robben J.; Robertson L.; Ruiz J.C.; Rutter S.; Saunders D.; Sch&#xE4;fer M.; Schein J.; Schwartz D.C.; Seeger K.; Seyler A.; Sharp S.; Shin H.; Sivam D.; Squares R.; Squares S.; Tosato V.; Vogt C.; Volckaert G.; Wambutt R.; Warren T.; Wedler H.; Woodward J.; Zhou S.; Zimmermann W.; Smith D.F.; Blackwell J.M.; Stuart K.D.; Barrell B.; Myler P.J.; The genome of the kinetoplastid parasite, Leishmania major. Science 2005,309(5733),436-442","journal-title":"Science"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/eji.200839017","volume":"39","author":"Bhaumik S.K.","year":"2009","unstructured":"Bhaumik S.K.; Naskar K.; De T.; Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10. Eur J Immunol 2009,39(8),2146-2160","journal-title":"Eur J Immunol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"105173","DOI":"10.1016\/j.actatropica.2019.105173","volume":"200","author":"Mohebali M.","year":"2019","unstructured":"Mohebali M.; Nadim A.; Khamesipour A.; An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines. Acta Trop 2019,200,105173","journal-title":"Acta Trop"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.ijantimicag.2010.06.024","volume":"36","author":"Modabber F.","year":"2010","unstructured":"Modabber F.; Leishmaniasis vaccines: Past, present and future. Int J Antimicrob Agents 2010,36(Suppl. 1),S58-S61","journal-title":"Int J Antimicrob Agents"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/CMR.14.2.229-243.2001","volume":"14","author":"Handman E.","year":"2001","unstructured":"Handman E.; Leishmaniasis: Current status of vaccine development. Clin Microbiol Rev 2001,14(2),229-243","journal-title":"Clin Microbiol Rev"},{"key":"ref=71","first-page":"942","volume":"27","author":"Tabbara K.S.","year":"2006","unstructured":"Tabbara K.S.; Progress towards a Leishmania vaccine. Saudi Med J 2006,27(7),942-950","journal-title":"Saudi Med J"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2249.2005.02768.x","volume":"140","author":"Khalil E A G.","year":"2005","unstructured":"Khalil E A G.; Ayed N.B.; Musa A.M.; Ibrahim M.E.; Mukhtar M.M.; Zijlstra E.E.; Elhassan I.M.; Smith P.G.; Kieny P.M.; Ghalib H.W.; Zicker F.; Modabber F.; Elhassan A.M.; Dichotomy of protective cellular immune responses to human visceral leishmaniasis. Clin Exp Immunol 2005,140(2),349-353","journal-title":"Clin Exp Immunol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.vetimm.2008.10.309","volume":"128","author":"Bourdoiseau G.","year":"2009","unstructured":"Bourdoiseau G.; Hugnet C.; Gon&#xE7;alves R.B.; V&#xE9;zilier F.; Petit-Didier E.; Papierok G.; Lemesre J.L.; Effective humoral and cellular immunoprotective responses in Li ESAp-MDP vaccinated protected dogs. Vet Immunol Immunopathol 2009,128(1-3),71-78","journal-title":"Vet Immunol Immunopathol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/0035-9203(61)90078-5","volume":"55","author":"Manson-Bahr P.E.C.","year":"1961","unstructured":"Manson-Bahr P.E.C.; Immunity in kala-azar. Trans R Soc Trop Med Hyg 1961,55(6),550-555","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1006\/expr.1996.4117","volume":"85","author":"Gicheru M.M.","year":"1997","unstructured":"Gicheru M.M.; Olobo J.O.; Anjili C.O.; Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease. Exp Parasitol 1997,85(2),109-116","journal-title":"Exp Parasitol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4049\/jimmunol.144.2.699","volume":"144","author":"Jaffe C.L.","year":"1990","unstructured":"Jaffe C.L.; Rachamim N.; Sarfstein R.; Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J Immunol 1990,144(2),699-706","journal-title":"J Immunol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.4049\/jimmunol.150.6.2322","volume":"150","author":"Rachamim N.","year":"1993","unstructured":"Rachamim N.; Jaffe C.; Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J Immunol 1993,150(6),2322-2331","journal-title":"J Immunol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1128\/iai.63.5.2062-2069.1995","volume":"63","author":"Wilson M.E.","year":"1995","unstructured":"Wilson M.E.; Young B.M.; Andersen K.P.; Weinstock J.V.; Metwali A.; Ali K.M.; Donelson J.E.; A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun 1995,63(5),2062-2069","journal-title":"Infect Immun"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.4049\/jimmunol.165.12.7064","volume":"165","author":"St&#xE4;ger S.","year":"2000","unstructured":"St&#xE4;ger S.; Smith D.F.; Kaye P.M.; Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 2000,165(12),7064-7071","journal-title":"J Immunol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1016\/S0264-410X(01)00023-8","volume":"19","author":"Ghosh A.","year":"2001","unstructured":"Ghosh A.; Labrecque S.; Matlashewski G.; Protection against Leishmania donovani infection by DNA vaccination: Increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 2001,19(23-24),3169-3178","journal-title":"Vaccine"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","volume":"20","author":"Ghosh A.","year":"2001","unstructured":"Ghosh A.; Zhang W.W.; Matlashewski G.; Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001,20(1-2),59-66","journal-title":"Vaccine"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","volume":"174","author":"Basu R.","year":"2005","unstructured":"Basu R.; Bhaumik S.; Basu J.M.; Naskar K.; De T.; Roy S.; Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: Evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 2005,174(11),7160-7171","journal-title":"J Immunol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pt.2005.03.006","volume":"21","author":"Coler R.","year":"2005","unstructured":"Coler R.; Reed S.; Second-generation vaccines against leishmaniasis. Trends Parasitol 2005,21(5),244-249","journal-title":"Trends Parasitol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1016\/j.vaccine.2005.07.001","volume":"23","author":"Gradoni L.","year":"2005","unstructured":"Gradoni L.; Foglia Manzillo V.; Pagano A.; Piantedosi D.; De Luna R.; Gramiccia M.; Scalone A.; Di Muccio T.; Oliva G.; Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 2005,23(45),5245-5251","journal-title":"Vaccine"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1128\/IAI.68.2.630-636.2000","volume":"68","author":"Suffia I.","year":"2000","unstructured":"Suffia I.; Ferrua B.; Stien X.; Mograbi B.; Marty P.; Rousseau D.; Fragaki K.; Kubar J.; A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis. Infect Immun 2000,68(2),630-636","journal-title":"Infect Immun"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0264-410X(01)00427-3","volume":"20","author":"Gonzalo R.M.","year":"2002","unstructured":"Gonzalo R.M.; del Real G.; Rodriguez J.R.; Rodriguez D.; Heljasvaara R.; Lucas P.; Larraga V.; Esteban M.; A heterologous prime\u2013boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36\/LACK antigen protects BALB\/c mice from cutaneous leishmaniasis. Vaccine 2002,20(7-8),1226-1231","journal-title":"Vaccine"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/S0264-410X(03)00032-X","volume":"21","author":"Ramiro M.J.","year":"2003","unstructured":"Ramiro M.J.; Z&#xE1;rate J.J.; Hanke T.; Rodriguez D.; Rodriguez J.R.; Esteban M.; Lucientes J.; Castillo J.A.; Larraga V.; Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 2003,21(19-20),2474-2484","journal-title":"Vaccine"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1128\/IAI.69.8.4719-4725.2001","volume":"69","author":"Melby P.C.","year":"2001","unstructured":"Melby P.C.; Yang J.; Zhao W.; Perez L.E.; Cheng J.; Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 2001,69(8),4719-4725","journal-title":"Infect Immun"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1086\/374783","volume":"187","author":"Daneshvar H.","year":"2003","unstructured":"Daneshvar H.; Coombs G.H.; Hagan P.; Phillips R.S.; Leishmania mexicana and Leishmania major: Attenuation of wild-type parasites and vaccination with the attenuated lines. J Infect Dis 2003,187(10),1662-1668","journal-title":"J Infect Dis"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/icb.1984.14","volume":"62","author":"Mitchell G.F.","year":"1984","unstructured":"Mitchell G.F.; Handman E.; Spithill T.W.; Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust J Exp Biol Med Sci 1984,62(2),145-153","journal-title":"Aust J Exp Biol Med Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1568008023340631","volume":"2","author":"Mau&#xEB;l J.","year":"2002","unstructured":"Mau&#xEB;l J.; Vaccination against Leishmania infections. Curr Drug Targets Immune Endocr Metabol Disord 2002,2(3),201-226","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1128\/CVI.00338-14","volume":"21","author":"Craft N.","year":"2014","unstructured":"Craft N.; Birnbaum R.; Quanquin N.; Erfe M.C.B.; Quant C.; Haskell J.; Bruhn K.W.; Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice. Clin Vaccine Immunol 2014,21(9),1314-1322","journal-title":"Clin Vaccine Immunol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"e2225","DOI":"10.1371\/journal.pntd.0002225","volume":"7","author":"Foglia Manzillo V.","year":"2013","unstructured":"Foglia Manzillo V.; Di Muccio T.; Cappiello S.; Scalone A.; Paparcone R.; Fiorentino E.; Gizzarelli M.; Gramiccia M.; Gradoni L.; Oliva G.; Prospective study on the incidence and progression of clinical signs in na&#xEF;ve dogs naturally infected by Leishmania infantum. PLoS Negl Trop Dis 2013,7(5),e2225","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"e1019","DOI":"10.1371\/journal.pntd.0001019","volume":"5","author":"Boggiatto P.M.","year":"2011","unstructured":"Boggiatto P.M.; Gibson-Corley K.N.; Metz K.; Gallup J.M.; Hostetter J.M.; Mullin K.; Petersen C.A.; Transplacental transmission of Leishmania infantum as a means for continued disease incidence in North America. PLoS Negl Trop Dis 2011,5(4),e1019","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.pt.2008.05.003","volume":"24","author":"Mir&#xF3; G.","year":"2008","unstructured":"Mir&#xF3; G.; Cardoso L.; Pennisi M.G.; Oliva G.; Baneth G.; Canine leishmaniosis \u2013 new concepts and insights on an expanding zoonosis: Part two. Trends Parasitol 2008,24(8),371-377","journal-title":"Trends Parasitol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1017\/S003118201100148X","volume":"138","author":"Franco A.O.","year":"2011","unstructured":"Franco A.O.; Davies C.R.; Mylne A.; Dedet J.P.; G&#xE1;llego M.; Ballart C.; Gramiccia M.; Gradoni L.; Molina R.; G&#xE1;lvez R.; Morillas-M&#xE1;rquez F.; Bar&#xF3;n-L&#xF3;pez S.; Pires C.A.; Afonso M.O.; Ready P.D.; Cox J.; Predicting the distribution of canine leishmaniasis in western Europe based on environmental variables. Parasitology 2011,138(14),1878-1891","journal-title":"Parasitology"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-308X(04)57001-X","volume":"57","author":"Alvar J.","year":"2004","unstructured":"Alvar J.; Ca&#xF1;avate C.; Molina R.; Moreno J.; Nieto J.; Canine Leishmaniasis. Adv Parasitol 2004,57,1-88","journal-title":"Adv Parasitol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"5964","DOI":"10.1016\/j.vaccine.2009.07.069","volume":"27","author":"Carcel&#xE9;n J.","year":"2009","unstructured":"Carcel&#xE9;n J.; Iniesta V.; Fern&#xE1;ndez-Cotrina J.; Serrano F.; Parejo J.C.; Corraliza I.; Gallardo-Soler A.; Mara&#xF1;&#xF3;n F.; Soto M.; Alonso C.; G&#xF3;mez-Nieto C.; The Chimerical Multi-Component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection. Vaccine 2009,27(43),5964-5973","journal-title":"Vaccine"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.vetpar.2013.05.008","volume":"197","author":"Bongiorno G.","year":"2013","unstructured":"Bongiorno G.; Paparcone R.; Manzillo V.F.; Oliva G.; Cuisinier A.M.; Gradoni L.; Vaccination with LiESP\/QA-21 (CaniLeish) reduces the intensity of infection in Phlebotomus perniciosus fed on Leishmania infantum infected dogs\u2014A preliminary xenodiagnosis study. Vet Parasitol 2013,197(3-4),691-695","journal-title":"Vet Parasitol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vetpar.2009.05.022","volume":"165","author":"Solano-Gallego L.","year":"2009","unstructured":"Solano-Gallego L.; Koutinas A.; Mir&#xF3; G.; Cardoso L.; Pennisi M.G.; Ferrer L.; Bourdeau P.; Oliva G.; Baneth G.; Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet Parasitol 2009,165(1-2),1-18","journal-title":"Vet Parasitol"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501254585230927100440","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/221704\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501254585230927100440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T15:34:12Z","timestamp":1704900852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/221704\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":100,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501254585230927100440","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}